Biogen teams up with gene-editing startup Scribe on ALS prog...

Scribe Therapeutics, a start-up focusing on gene-editing using CRISPR/Cas9, has burst onto the biotech scene with a $415 million deal with Biogen.

Biohaven ALS drug blocked by FDA over manufacturing issue